{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:57:01Z","timestamp":1778122621394,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Arab Journal of Gastroenterology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ajg.2018.02.007","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T04:11:38Z","timestamp":1529554298000},"page":"51-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of PPI-resistant gastro-oesophageal reflux: A systematic review"],"prefix":"10.1016","volume":"19","author":[{"given":"Giulia","family":"Gallusi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Pontone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajg.2018.02.007_b0005","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2036.2009.04047.x","article-title":"Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia","volume":"30","author":"Hungin","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajg.2018.02.007_b0010","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3109\/00365529709011212","article-title":"Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response","volume":"32","author":"Lind","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ajg.2018.02.007_b0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","article-title":"Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease\u2014where next?","volume":"22","author":"Fass","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajg.2018.02.007_b0020","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"10.1016\/j.ajg.2018.02.007_b0025","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/j.1365-2036.2007.03529.x","article-title":"Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors\u2014a follow-up study of intraluminal-impedance guided therapy","volume":"26","author":"Becker","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajg.2018.02.007_b0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000221146","article-title":"High-dose esomeprazole for treatment of symptomatic refractory gastroesophageal reflux disease\u2014a prospective ph-metry\/ impedance-controlled study","volume":"80","author":"Bajbouj","year":"2009","journal-title":"Digestion"},{"key":"10.1016\/j.ajg.2018.02.007_b0035","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1136\/gut.52.10.1397","article-title":"Effect of the GABAB agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors","volume":"52","author":"Koek","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.ajg.2018.02.007_b0040","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2009.247","article-title":"Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?","author":"Beaumont","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ajg.2018.02.007_b0045","first-page":"3272","article-title":"Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux","volume":"17","author":"Palmieri","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ajg.2018.02.007_b0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/apt.12363","article-title":"Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease\u2014insights into study design for transient lower sphincter relaxation inhibitors","volume":"38","author":"Vakil","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajg.2018.02.007_b0055","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2169\/internalmedicine.49.3615","article-title":"Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GORD (FSSG) on decision of treatment strategy","volume":"49","author":"Miyamoto","year":"2010","journal-title":"Inter Med"},{"key":"10.1016\/j.ajg.2018.02.007_b0060","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00535-009-0173-0","article-title":"The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying","volume":"45","author":"Futagami","year":"2010","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ajg.2018.02.007_b0065","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00535-011-0446-2","volume":"46","author":"Furuta","year":"2011","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ajg.2018.02.007_b0070","first-page":"178","article-title":"A stepwise protocol for the treatment of refractory gastroesophageal reflux-induced chronic cough","volume":"8","author":"Xu","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ajg.2018.02.007_b0075","doi-asserted-by":"crossref","unstructured":"Vakil N1, van Zanten SV, Kahrilas P, Dent J, Jones R. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global eviden ce-based consensus. Am J Gastroenterol 2006;101:1900\u201320.","DOI":"10.1111\/j.1572-0241.2006.00630.x"},{"key":"10.1016\/j.ajg.2018.02.007_b0080","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2036.2010.04550.x","article-title":"Weakly acidic refluxes have a major role in the pathogenesis of proton pump inhibitor-resistant reflux oesophagitis","volume":"33","author":"Frazzoni","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ajg.2018.02.007_b0085","first-page":"546","article-title":"Current concepts in the pathogenesis and treatment of reflux esophagitis","volume":"2","author":"Frazier","year":"1983","journal-title":"Clin Pharm"},{"key":"10.1016\/j.ajg.2018.02.007_b0090","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1018881617038","article-title":"Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor","volume":"43","author":"Haga","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ajg.2018.02.007_b0095","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.bjc.6605024","article-title":"Proton pump inhibitors and risk of gastric cancer: a population-based cohort study","volume":"100","author":"Poulsen","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajg.2018.02.007_b0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1586\/ecp.12.20","article-title":"Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis","volume":"5","author":"Giuliano","year":"2012","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Arab Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197918300200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197918300200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T20:00:53Z","timestamp":1571515253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1687197918300200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1687197918300200"],"URL":"https:\/\/doi.org\/10.1016\/j.ajg.2018.02.007","relation":{},"ISSN":["1687-1979"],"issn-type":[{"value":"1687-1979","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of PPI-resistant gastro-oesophageal reflux: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Arab Journal of Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajg.2018.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}